Cisplatin
Cisplatin (cisplatin) is a small molecule pharmaceutical. Cisplatin was first approved as Cisplatin on 1982-01-01. It is used to treat amelanotic melanoma, astrocytoma, breast neoplasms, cystic mesothelioma, and esophageal neoplasms amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cisplatin (discontinued: Cisplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cisplatin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CISPLATIN | HQ Specialty Pharma | N-018057 RX | 1982-01-01 | 2 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cisplatin | New Drug Application | 2026-06-24 |
Indications
FDA
EMA
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9060 | Injection, cisplatin, powder or solution, 10 mg |
Clinical
Clinical Trials
5333 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 174 | 497 | 276 | 21 | 52 | 929 |
| Lung neoplasms | D008175 | — | C34.90 | 116 | 324 | 134 | 11 | 47 | 570 |
| Carcinoma | D002277 | — | C80.0 | 83 | 294 | 120 | 3 | 70 | 529 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 96 | 254 | 89 | 1 | 37 | 438 |
| Neoplasms | D009369 | — | C80 | 218 | 183 | 51 | 5 | 28 | 416 |
| Head and neck neoplasms | D006258 | — | — | 80 | 200 | 71 | 4 | 40 | 361 |
| Squamous cell carcinoma | D002294 | — | — | 66 | 202 | 55 | 3 | 38 | 334 |
| Uterine cervical neoplasms | D002583 | — | — | 46 | 146 | 91 | 2 | 49 | 311 |
| Nasopharyngeal neoplasms | D009303 | — | — | 19 | 140 | 100 | 1 | 26 | 266 |
| Esophageal neoplasms | D004938 | — | C15 | 38 | 159 | 54 | 5 | 23 | 253 |
Show 51 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasopharyngeal carcinoma | D000077274 | — | — | 18 | 143 | 114 | — | 30 | 287 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 52 | 84 | 35 | — | 20 | 174 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 35 | 99 | 14 | — | 10 | 139 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 31 | 79 | 29 | — | 10 | 130 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 23 | 50 | 25 | — | 15 | 108 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 37 | 74 | 10 | — | 6 | 108 |
| Recurrence | D012008 | — | — | 15 | 54 | 21 | — | 10 | 92 |
| Malignant mesothelioma | D000086002 | — | — | 36 | 57 | 8 | — | 4 | 86 |
| Mesothelioma | D008654 | — | C45 | 35 | 54 | 9 | — | 6 | 84 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 9 | 38 | 21 | — | 14 | 75 |
Show 179 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Deafness | D003638 | EFO_0001063 | H91.9 | 2 | 5 | — | — | 5 | 11 |
| Pleural effusion | D010996 | — | J90 | 2 | 5 | — | — | 3 | 10 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 5 | 5 | — | — | — | 8 |
| Glandular and epithelial neoplasms | D009375 | — | — | 2 | 7 | — | — | 1 | 8 |
| Hyperthermic intraperitoneal chemotherapy | D000084262 | — | — | 2 | 4 | — | — | 2 | 8 |
| Pleural solitary fibrous tumor | D054363 | — | — | 1 | 6 | — | — | — | 6 |
| Large-cell lymphoma immunoblastic | D016400 | — | — | 1 | 5 | — | — | — | 6 |
| Renal insufficiency | D051437 | — | N19 | 2 | 1 | — | — | 3 | 6 |
| Cystadenocarcinoma | D003536 | — | — | 3 | 1 | — | — | 1 | 5 |
| Plasmacytoma | D010954 | — | C90.3 | — | 5 | — | — | — | 5 |
Show 157 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Appendiceal neoplasms | D001063 | EFO_0003880 | C18.1 | 3 | — | — | — | 2 | 5 |
| Circulating neoplastic cells | D009360 | — | — | 1 | — | — | — | 2 | 3 |
| Pinealoma | D010871 | — | — | 3 | — | — | — | — | 3 |
| And serous mucinous cystic neoplasms | D018297 | — | — | 1 | — | — | — | — | 1 |
| Mullerian mixed tumor | D018200 | — | — | 1 | — | — | — | — | 1 |
| Parotid neoplasms | D010307 | EFO_0003873 | C07 | 1 | — | — | — | — | 1 |
| Hydronephrosis | D006869 | EFO_0005562 | N13.30 | 1 | — | — | — | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | — | — | — | — | 1 |
| Subependymal glioma | D018315 | EFO_1001197 | — | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 3 | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 3 | 3 |
| Cervical intraepithelial neoplasia | — | — | D06 | — | — | — | — | 2 | 2 |
| Uterine cervical dysplasia | D002578 | EFO_1000910 | N87 | — | — | — | — | 2 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 2 | 2 |
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | — | — | — | 2 | 2 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 2 | 2 |
| Acupuncture therapy | D015670 | — | — | — | — | — | — | 2 | 2 |
| Carcinogenesis | D063646 | — | — | — | — | — | — | 1 | 1 |
| Methylation | D008745 | — | — | — | — | — | — | 1 | 1 |
Show 57 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cisplatin |
| INN | cisplatin |
| Description | Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | antineoplastics (platinum derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 15663-27-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL11359 |
| ChEBI ID | — |
| PubChem CID | 5702198 |
| DrugBank | DB00515 |
| UNII ID | Q20Q21Q62J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 159,289 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cisplatin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
77,027 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use